MA53604A - Anticorps agonistes de cd200r et utilisations de ces derniers - Google Patents

Anticorps agonistes de cd200r et utilisations de ces derniers

Info

Publication number
MA53604A
MA53604A MA053604A MA53604A MA53604A MA 53604 A MA53604 A MA 53604A MA 053604 A MA053604 A MA 053604A MA 53604 A MA53604 A MA 53604A MA 53604 A MA53604 A MA 53604A
Authority
MA
Morocco
Prior art keywords
agonist antibodies
cd200r agonist
cd200r
antibodies
agonist
Prior art date
Application number
MA053604A
Other languages
English (en)
French (fr)
Inventor
Stephen John Demarest
Anja Koester
Payal Mehta
Scott Charles Potter
Diana Isabel Ruiz
Derrick Ryan Witcher
Xiufeng Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53604A publication Critical patent/MA53604A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053604A 2018-09-14 2019-09-11 Anticorps agonistes de cd200r et utilisations de ces derniers MA53604A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14

Publications (1)

Publication Number Publication Date
MA53604A true MA53604A (fr) 2021-12-22

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053604A MA53604A (fr) 2018-09-14 2019-09-11 Anticorps agonistes de cd200r et utilisations de ces derniers

Country Status (27)

Country Link
US (2) US11319370B2 (https=)
EP (1) EP3849667A1 (https=)
JP (3) JP7185051B2 (https=)
KR (1) KR102705378B1 (https=)
CN (2) CN112739422B (https=)
AR (1) AR116668A1 (https=)
AU (1) AU2019339334B2 (https=)
BR (1) BR112021003254A2 (https=)
CA (1) CA3112763C (https=)
CL (1) CL2021000606A1 (https=)
CO (1) CO2021003093A2 (https=)
CR (1) CR20210134A (https=)
DO (1) DOP2021000040A (https=)
EA (1) EA202190530A1 (https=)
EC (1) ECSP21017619A (https=)
IL (1) IL281442B2 (https=)
JO (1) JOP20210048B1 (https=)
MA (1) MA53604A (https=)
MX (1) MX2021003026A (https=)
MY (1) MY196156A (https=)
NZ (1) NZ773626A (https=)
PE (1) PE20211742A1 (https=)
PH (1) PH12021550530A1 (https=)
SG (1) SG11202101697YA (https=)
TW (1) TWI749367B (https=)
WO (1) WO2020055943A1 (https=)
ZA (2) ZA202101246B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
PE20251170A1 (es) * 2022-04-06 2025-04-23 Mirobio Ltd Anticuerpos cd200r disenados por ingenieria y usos de estos
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
AU2024282979A1 (en) 2023-06-02 2026-01-22 Aimed Bio Inc. Anti-cd200r1 antibody and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
KR20090094846A (ko) 2006-12-22 2009-09-08 쉐링 코포레이션 Ｃｄ200ｒ에 대한 항체
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) * 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
CO2021003093A2 (es) 2021-03-19
ECSP21017619A (es) 2021-04-29
JP7490025B2 (ja) 2024-05-24
NZ773626A (en) 2024-11-29
CA3112763A1 (en) 2020-03-19
EP3849667A1 (en) 2021-07-21
IL281442A (en) 2021-04-29
DOP2021000040A (es) 2021-03-31
SG11202101697YA (en) 2021-04-29
US11319370B2 (en) 2022-05-03
KR102705378B1 (ko) 2024-09-12
MY196156A (en) 2023-03-17
TW202024132A (zh) 2020-07-01
TWI749367B (zh) 2021-12-11
ZA202101246B (en) 2023-04-26
JOP20210048A1 (ar) 2021-03-11
CN118530360A (zh) 2024-08-23
AU2019339334B2 (en) 2023-03-09
JP2022500080A (ja) 2022-01-04
CR20210134A (es) 2021-03-29
US20200087395A1 (en) 2020-03-19
ZA202204978B (en) 2022-09-28
WO2020055943A1 (en) 2020-03-19
AR116668A1 (es) 2021-06-02
BR112021003254A2 (pt) 2021-05-18
EA202190530A1 (ru) 2021-06-21
IL281442B1 (en) 2023-11-01
JP7185051B2 (ja) 2022-12-06
PE20211742A1 (es) 2021-09-06
KR20210044262A (ko) 2021-04-22
CL2021000606A1 (es) 2021-09-20
PH12021550530A1 (en) 2022-02-14
IL281442B2 (en) 2024-03-01
MX2021003026A (es) 2021-05-27
CA3112763C (en) 2024-05-14
JOP20210048B1 (ar) 2024-12-22
JP2022141959A (ja) 2022-09-29
CN112739422A (zh) 2021-04-30
AU2019339334A1 (en) 2021-03-18
US20220251198A1 (en) 2022-08-11
JP2024105529A (ja) 2024-08-06
CN112739422B (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
EP3898693A4 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
EP3762030A4 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
EP3684812A4 (en) ANTI-CTLA4 ANTIBODIES AND USES THEREOF
EP3838289A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3589660A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND USES THEREOF
EP3897719A4 (en) Protease cleavable bispecific antibodies and uses thereof
EP3820484A4 (en) ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF
EP3587453A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3626825A4 (en) ANTI-CDH6 ANTIBODIES AND ANTI-CDH6 ANTIBODY INGREDIENT CONJUGATE
EP4261231A4 (en) Bispecific antibody and application thereof
EP3400243A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
MA49398A (fr) Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
EP3693390A4 (en) SPECIFIC ANTIBODIES AGAINST CD47 AND PD-L1
MA53604A (fr) Anticorps agonistes de cd200r et utilisations de ces derniers
EP3990498A4 (en) ANTI-CD24 ANTIBODIES AND USES THEREOF
EP3999545A4 (en) ANTI-CD73 ANTIBODIES AND USE THEREOF
EP3604338A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
EP3733702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
EP3473649A4 (en) MONOCLONAL ANTI-CD47 ANTIBODIES AND USES THEREOF
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
EP3845244A4 (en) ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
EP3883967A4 (en) CD38 AND ICAM1 ANTIBODIES AND USES THEREOF